Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients. A pharmaco-economic study based on a meta-analysis

South African Medical Journal

Volumn 88, Issue 3, 1998, Pages 251-255

  Wessels, François ^a   Anderson, A Nixon ^b   Ebrahim, Osman ^c,d  

^a Outcomes Consultants   (South Africa)

^b Anderson Kropman cc   (South Africa)

^c Roche Products (Pty) Ltd

^d Roche Products (Proprietary) Ltd   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; CEPHALOSPORIN; CLAVULANIC ACID;

ANTIBIOTIC THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; ORAL DRUG ADMINISTRATION; PNEUMONIA; PRIVATE HOSPITAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HOSPITAL COSTS; HUMANS; INFANT; LENGTH OF STAY; ODDS RATIO; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 0031972008     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bohte R, Van Wout JW, Lobatto S, et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1995; 14: 182-187.
2. Rello J, Quintana E, Ausina V, Net A, Prats G, A three-year study of severe community-acquired pneumonia with emphasis on outcome. Chest 1993; 103(1): 232-235.
3. Bradshaw D, Botha H, Joubert G, Pretorius JP, Van Wyk R, Yach D. Review of South African Mortality (1984) (MRC Technical Report No. 1). Parowvallei, W. Cape: Medical Research Council, 1987.
4. Community-acquired pneumonia guidelines. S Afr Med J 1996; 86: 1152-1163.
5. Mulrow CD. Systematic review: rationale for systematic reviews. BMJ 1994; 309: 597-599.
6. Brambilla C, Kastanakis S, Knight S, Cunningham K. Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis 1992; 11: 118-124.
7. Dansey RD, Jacka PJ, Strachan SA, Hay M. Comparison of cefotaxime with ceftriaxone given intramuscularly 12-hourly for community-acquired pneumonia. Diagn Microbiol Infect Dis 1992; 15: 81-84.
8. Myburgh J, Nagel GJ, Petschel E. The efficacy and tolerance of a three-day course of azithromycin in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1993; 31: 163-169.
9. Dillon-Bader VL, Glenski S, Vickers M. A comparative, retrospective, outcomes analysis of Rocephin 1 gram q24 vs. cefizox 1 gram q12 in the treatment of patients with community-acquired pneumonia. Can J Infect Dis 1995; 6: 4120.
10. Baumgartner JD, Glauser MP. Tolerance study of ceftriaxone compared with amoxicillin in patients with pneumonia. Am J Med 1984; 77: 54-58.
11. Barradas P, Zamith M, Videira W, Cardosa T, Marques RA, Avila R. Therapy of tower respiratory tract infections: a comparison of ceftriaxone and cefotaxime. Chemotherapy 1989; 35: suppl 2, 33-40.
12. Gris P. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomised, double-blind comparative study. J Antimicrob Chemother 1996; 37: suppl C, 93-101.
13. Lode H, Garau J, Grassi C, et al. Treatment of community-acquired pneumonia: a randomised comparison of sparfloxacin, amoxicillin-clavulanic acid and erythromycin. Eur Respir J 1995; 8: 1999-2007.
14. Schleupner CJ, Engle JC. Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections. Antimicrob Agents Chemother 1982; 21: 327-333.
15. Segev S, Kitzes R, Rubinstein E, Pitlik S, Samra Y, Shenkman L, Weinberg M. Ceftizoxime vs. cefotaxime - a comparative randomised multicenter study. 1sr J Med Sci 1988; 24: 410-414.
16. Brown R. Pneumonia and lower respiratory tract infections. Hosp Pract 1991; 26: suppl 5, 37-42.
17. Karachalios GN. Treatment of respiratory tract infections with a combination of amoxicillin and clavulanic acid. Int J Clin Pharmacol Ther 1985; 23: 647-649.
18. Barckow D, Schwigon C-D. Cefepime versus cefotaxime in the treatment of lower respiratory tract infections. J Antimicrob Chemother 1993; 32: suppl B, 187-193.
19. Gaillat J, Bru JP, Sedalian A. Penicillin G/floxacín versus erythromycin/amoxicillin-clavulanate in the treatment of severe community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1994; 13: 639-644.
20. Vogel F, Lode H. The use of oral temafloxacin compared with parenteral cephalosporin in hospitalised patients with pneumonia. J Antimicrob Chemother 1991; 28: suppl C, 81-86.
21. Gladen HE. Evaluating the cost-effectiveness of treatment with third-generation cephalosporins. Diagn Microbiol Infect Dis 1992; 15: 99-105.
22. Balmes P, Clerc G, Dupont B, Labram C, Pariente R, Poirier R. Comparative study of azithromycin and amoxicillin/clavulanic acid in the treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis 1991; 10: 437-439.
23. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greehe JG. A prospective randomised study of inpatient IV antibiotics for community-acquired pneumonia - the optimal duration of therapy. Chest 1996; 110: 965-971.
24. Brown RB. Ceftriaxone for lower respiratory tract infections in adults. Review of Contemporary Pharmacotherapy 1995; 6: 391-399.